May 9, 2023 Arcutis First Quarter 2023 Financial Results & Business Update December 15, 2022 ARQT December 2022 Corporate Overview December 12, 2022 Arcutis BioTherapeutics Phase 3 Atopic Dermatitis Topline Data Presentation August 1, 2022 Arcutis ZORYVE FDA Approval Presentation June 14, 2022 Seborrheic Dermatitis Phase 3 STRATUM Topline Presentation March 28, 2022 Arcutis Investor Day Presentation February 1, 2021 DERMIS-1/DERMIS-2 Phase 3 Plaque Psoriasis Topline Data Review December 9, 2020 Arcutis 2020 Virtual Investor Day November 23, 2020 Phase 2b Study of Roflumilast Foam in Adolescents and Adults with Scalp and Body Psoriasis September 29, 2020 Arcutis Roflumilast Foam Seb Derm Patient Impact Infographic Current page 1 Page 2 Next page next › Last page last »
November 23, 2020 Phase 2b Study of Roflumilast Foam in Adolescents and Adults with Scalp and Body Psoriasis
